Oral components

Abstract

To provide an oral composition in which the reduction in the bactericidal activity of cationic surfactants due to saliva is suppressed. [Solution] (A) Cationic surfactant, and (B) At least one selected from the group consisting of monosaccharides and monosaccharide alcohols An oral composition containing, (A) is at least one selected from the group consisting of C12-16 alkylpyridinium salts, benzalkonium salts, benzethonium salts, and cocoyl arginine ethyl salts, and (B) is at least one selected from the group consisting of xylose, mannitol, arabinose, ribose, glucose, fructose, and sorbitol. Oral composition.

Description

Technical Field

[0001] The present disclosure relates to oral compositions and the like, and more particularly to oral compositions containing a cationic surfactant. The content of all documents described in this specification is incorporated herein by reference.

Background Art

[0002] It is known that cationic surfactants may be used as bactericides.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0004] Some cationic surfactants are used as bactericides in the field of oral compositions. Examples of such cationic surfactants include quaternary ammonium compounds (especially quaternary ammonium salts) and amino acid-based cationic surfactants. More specifically, for example, cetylpyridinium chloride (also denoted as "CPC") is a quaternary ammonium salt and is a bactericide widely used in oral compositions and the like.

[0005] The present inventors have found that when an oral composition containing a cationic surfactant is used, its bactericidal power may be reduced by saliva.

[0006] Therefore, in order to provide an oral composition containing a cationic surfactant that can be suitably applied in the oral cavity and in which the reduction of its bactericidal power by saliva during oral application is suppressed, investigations were conducted. [Means for solving the problem]

[0007] As a result of their extensive research, the inventors discovered that an oral composition containing a specific cationic surfactant together with a specific monosaccharide or monosaccharide alcohol may suppress the reduction in the bactericidal power of the cationic surfactant due to saliva, and they further refined the composition.

[0008] This disclosure includes, for example, the following subjects: Section 1. (A) Cationic surfactants, and (B) At least one selected from the group consisting of monosaccharides and monosaccharide alcohols An oral composition containing, (A) is at least one selected from the group consisting of C12-16 alkylpyridinium salts, benzalkonium salts, benzethonium salts, and cocoyl arginine ethyl salts, and (B) is at least one selected from the group consisting of xylose, mannitol, arabinose, ribose, glucose, fructose, and sorbitol. Oral composition. Section 2. The oral composition according to claim 1, wherein (A) is at least one selected from the group consisting of C12-16 alkylpyridinium chloride, benzalkonium chloride, benzethonium chloride, and cocoyl arginine ethyl PCA. Section 3. (B) is an oral composition according to item 1 or 2, wherein (B) contains xylose. Section 4. (A) contains 0.05 to 250 parts by mass of (B) per 1 part by mass of (A), An oral composition as described in any of items 1 to 3. Section 5. An oral composition according to any one of items 1 to 4, containing 0.01 to 0.3% by mass of (A). [Effects of the Invention]

[0009] Provided is an oral composition containing a cationic surfactant, in which the decrease in the bactericidal activity of the cationic surfactant due to saliva is suppressed.

Mode for Carrying Out the Invention

[0010] Hereinafter, each embodiment included in the present disclosure will be described in more detail. The present disclosure preferably includes oral compositions and the like, but is not limited thereto, and the present disclosure includes all that are disclosed herein and can be recognized by those skilled in the art.

[0011] The oral composition included in the present disclosure contains a specific cationic surfactant and a specific monosaccharide and / or monosaccharide alcohol. Hereinafter, the oral composition included in the present disclosure may be referred to as "the oral composition of the present disclosure".

[0012] The cationic surfactant contained in the oral composition of the present disclosure is at least one selected from the group consisting of a pyridinium salt having a C12 - 16 alkyl group (C12 - 16 alkylpyridinium salt), a benzalkonium salt, a benzetonium salt, and a cocoyl arginine ethyl salt. The specific cationic surfactant may be referred to as the "(A) component".

[0013] As the C12 - 16 (12, 13, 14, 15, or 16) alkylpyridinium salt, a chloride salt or a bromide salt is preferable. The alkyl group may be linear or branched, and is preferably linear. For example, a C12 - 15 alkylpyridinium salt may also be used.

[0014] More specifically, as the C12 - 16 alkylpyridinium salt, for example, formula (1):

[0015]

Chemical formula

[0016] (In the formula, R represents a C12 - 16 linear alkyl group, and X represents Cl or Br), and the compounds represented thereby are preferably mentioned. Also, "C number" represents the number of carbon atoms. Also, the compound represented by the formula (1) may be referred to as "compound (1)".

[0017] Among the compounds (1), the formula (1a):

[0018] [Chemical formula]

[0019] (In the formula, R is the same as above), and the compounds represented thereby are more preferable. Note that dodecylpyridinium chloride (DPC) is a compound in which -R is -(CH2) 11 CH3 in the formula (1a), and cetylpyridinium chloride (CPC) is a compound in which -R is -(CH2) 15 CH3 in the formula (1a).

[0020] As the benzalkonium salt, a chloride salt or a bromide salt is preferable, and a chloride salt (that is, benzalkonium chloride) is more preferable. As the benzethonium salt, a chloride salt or a bromide salt is preferable, and a chloride salt (that is, benzethonium chloride) is more preferable. As the cocoyl arginine ethyl salt, for example, a pyrrolidone carboxylic acid (PCA) salt (that is, cocoyl arginine ethyl PCA) is preferable.

[0021] The cationic surfactant can be used alone or in combination of two or more.

[0022] The specific monosaccharides and / or monosaccharide alcohols contained in the oral compositions of this disclosure are xylose, mannitol, arabinose, ribose, glucose, fructose, and sorbitol. Both D- and L-isomers of these can be used. Preferably, the L-isomer of arabinose and the D-isomers of the others are used. These specific monosaccharides and / or sugar alcohols can be used individually or in combination. These specific monosaccharides and / or sugar alcohols may be referred to as "(B) component."

[0023] In the oral composition of this disclosure, preferably, component (B) is contained in an amount of about 0.05 to 250 parts by mass per 1 part by mass of component (A). The upper or lower limits of the range are, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 1 22, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175 ,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,22 The amount may be 9, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, or 249 parts by mass. For example, the range may be 0.1 to 200 parts by mass.

[0024] In the oral compositions of this disclosure, component (A) is preferably contained in an amount of about 0.01 to 0.3% by mass. The upper or lower limit of this range may be, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, or 0.29% by mass. For example, the range may be 0.02 to 0.09% by mass.

[0025] In the oral compositions of this disclosure, component (B) is preferably contained in an amount of about 0.005 to 50% by mass. The upper or lower limits of this range are, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.05, and 1.1. , 1.15, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 30.5, 31, 31.5, 32, The mass percentage may be 32.5, 33, 33.5, 34, 34.5, 35, 35.5, 36, 36.5, 37, 37.5, 38, 38.5, 39, 39.5, 40, 40.5, 41, 41.5, 42, 42.5, 43, 43.5, 44, 44.5, 45, 45.5, 46, 46.5, 47, 47.5, 48, 48.5, 49, or 49.5%. For example, the range may be 0.01 to 20% by mass.

[0026] Furthermore, the oral compositions of this disclosure preferably have a pH of 4 to 9. The upper or lower limits of this pH range may be, for example, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, or 8.9. For example, the pH range may be 5 to 8.

[0027] The oral compositions of this disclosure can be manufactured by known methods or by methods readily conceivable from known methods. Furthermore, the oral compositions of this disclosure can be used, for example, as pharmaceuticals, quasi-drugs, or cosmetics. The form of the oral compositions of this disclosure is not particularly limited, but can be in the form (dosage form) of, for example, ointments, pastes, pastes, gels, liquids, sprays, mouthwashes, liquid toothpastes, toothpastes, or topical applications.

[0028] In addition to components (A) and (B), the oral composition of this disclosure may further contain, either alone or in combination of two or more optional components, provided that they do not impair the effects of the present invention.

[0029] For example, surfactants other than component (A) may be added. Specifically, for example, nonionic surfactants, anionic surfactants, or amphoteric surfactants may be added as surfactants. More specifically, examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers with a polyoxyethylene addition coefficient of 8 to 10 and 13 to 15 carbon atoms in the alkyl group; polyoxyethylene alkylphenyl ethers with a polyoxyethylene addition coefficient of 10 to 18 and 9 carbon atoms in the alkyl group; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan; alkyl glucosides with 8 to 16 carbon atoms in the alkyl group, etc. Examples of anionic surfactants include sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; acyl amino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methylalanine; and sodium cocoyl methyl taurate. Examples of amphoteric surfactants include betaine-type activators such as lauryl dimethylaminoacetic acid betaine and coconut oil fatty acid amidopropyl dimethylaminoacetic acid betaine; imidazoline-type activators such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium; and amino acid-type activators such as N-lauryldiaminoethylglycine. Coconut oil fatty acid monoethanolamide, coconut oil fatty acid diethanolamide, coconut oil fatty acid amide betaine, and coconut oil fatty acid amidopropyl betaine are also preferred examples. These surfactants can be blended individually or in combination of two or more. The amount blended is usually, for example, 0.1 to 5% by mass of the total amount of the composition.

[0030] Furthermore, sweeteners such as sodium saccharin, acesulfame potassium, stevioside, sucralose, neohesperidyl dihydrochalcone, perillartin, thaumatin, aspartylphenylalanyl methyl ester, and p-methoxycinnamic aldehyde may be included. These can be used individually or in combination of two or more. They can also be included in amounts of, for example, 0.01 to 1% by mass relative to the total amount of the composition.

[0031] Furthermore, as binders, one or more of the following can be used in combination: cellulose derivatives such as sodium carboxymethylcellulose, carboxymethyl ethylcellulose salt, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropyl methylcellulose; microbially produced polymers such as xanthan gum and gellan gum; natural polymers or natural rubbers such as tragacanth gum, karaya gum, arabic gum, carrageenan, and dextrin; synthetic polymers such as polyvinyl alcohol and polyvinylpyrrolidone; inorganic binders such as thickening silica and bee gum; and cationic binders such as O-[2-hydroxy-3-(trimethylammonio)propyl]hydroxyethylcellulose chloride.

[0032] Furthermore, humectants such as sorbitol, glycerin, propylene glycol, xylitol, maltitol, lactitol, and polyoxyethylene glycol can be included individually or in combination of two or more.

[0033] As preservatives, parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, sodium benzoate, phenoxyethanol, and alkyldiaminoethylglycine hydrochloride may be included individually or in combination of two or more.

[0034] As coloring agents, legally approved pigments such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3, mineral pigments such as ultramarine, enhanced ultramarine, and navy blue, and titanium dioxide may be blended individually or in combination of two or more.

[0035] As pH adjusters, citric acid, phosphoric acid, malic acid, pyrophosphate, lactic acid, tartaric acid, glycerophosphate, acetic acid, nitric acid, or chemically possible salts thereof, or sodium hydroxide may be included. These can be included individually or in combination of two or more so that the pH of the composition is in the range of, for example, 4 to 9, preferably 5 to 8. The amount of pH adjuster included is exemplified by 0.01 to 2% by weight.

[0036] Other bactericides besides component (A) may be included as active ingredients. Examples include cationic bactericides such as chlorhexidine hydrochloride and chlorhexidine gluconate, amphoteric bactericides such as dodecyldiaminoethylglycine, nonionic bactericides such as triclosan and isopropylmethylphenol, and hinokitiol. Furthermore, other active ingredients besides bactericides may also be included. For example, vitamin E derivatives such as aluminum lactate, potassium nitrate, dl-α-tocopherol acetate, tocopherol succinate, or tocopherol nicotinate, and sodium fluoride may be included. Active ingredients may be included individually or in combination of two or more.

[0037] Furthermore, it is possible to add base materials such as alcohols, silicones, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, and Plastibase, either individually or in combination of two or more.

[0038] Please note that the above list of optional components is for illustrative purposes only and does not limit the optional components that may be used.

[0039] The oral composition of this disclosure contains a combination of component (A) and component (B), thereby suppressing the reduction of the bactericidal activity of component (A) by saliva. As a result, the time required for sterilization is shorter compared to cases where the specific sugar is not contained. Therefore, it becomes possible to shorten the time required for oral care. Furthermore, the bactericidal activity of component (A) is preferably used in the oral composition for the sterilization of periodontal disease bacteria, for example. For this reason, although not particularly limited, the oral composition of this disclosure can also be preferably used for individuals carrying oral periodontal disease bacteria (especially patients with periodontal disease). Furthermore, since the reduction in the bactericidal power of component (A) due to saliva varies from person to person (for example, some people experience a significant reduction in the bactericidal power of component (A) due to saliva, while others experience a milder reduction), the oral compositions of this disclosure can be preferably used for subjects for whom suppression of the reduction in the bactericidal power of component (A) due to saliva is required (more specifically, for example, subjects whose bactericidal power of component (A) is reduced by saliva, subjects suffering from oral diseases caused by bacteria such as periodontal disease, etc.). In addition, the subjects include not only humans but also non-human mammals. For example, pets and livestock may also be included. More specifically, for example, dogs, cats, monkeys, cattle, horses, pigs, sheep, goats, mice, rats, etc.

[0040] This disclosure also includes a method for suppressing the reduction of the bactericidal activity of component (A) by saliva, which includes using component (A) and component (B) in combination, and a method for manufacturing an oral composition, which includes incorporating component (A) and component (B) into a composition.

[0041] In this specification, the term "comprising" includes both "consisting essentially of" and "consisting of." Furthermore, this disclosure encompasses all any combination of the constituent elements described herein.

[0042] Furthermore, the various characteristics (properties, structure, function, etc.) described for each embodiment of this disclosure described above may be combined in any way to identify the subject matter covered by this disclosure. In other words, this disclosure encompasses all subject matter consisting of any combination of each of the combinatable properties described herein. [Examples]

[0043] The embodiments of this disclosure will be described in more detail below with examples, but the embodiments of this disclosure are not limited to the examples below.

[0044] Saliva collection Each subject (Subjects A-E) was asked to brush their teeth with toothpaste that did not contain surfactants or disinfectants, and 10 mL of saliva (non-irritating saliva) was collected from each subject. The collected saliva was stored in the refrigerator, and immediately before use, it was aspirated and dispensed five times using a 23G injection needle and a 10 mL syringe (both manufactured by Terumo Corporation) before being used.

[0045] Preparation of the test drug solution The bactericidal components used were cetylpyridinium chloride (CPC), dodecylpyridinium chloride (DPC), cocoyl arginine ethyl PCA (CAE), benzalkonium chloride, and benzethonium chloride.

[0046] Aqueous solutions of the test drug were prepared containing 0.05% (w / v) cetylpyridinium chloride (CPC) and 0.5% (w / v) each sugar (see Table 1).

[0047] In addition, aqueous solutions of the test drug containing 0.05% (w / v) dodecylpyridinium chloride (DPC) and 0.01%, 0.1%, 0.5%, 1%, or 10% (w / v) of each sugar were prepared (see Table 2).

[0048] Furthermore, aqueous solutions of the test drug containing 0.02%, 0.05%, or 0.1% (w / v) of cocoyl arginine ethyl PCA (CAE) and 0.1% or 0.5% (w / v) of D-xylose were prepared (see Table 3).

[0049] Furthermore, aqueous solutions of the test drug containing 0.01 (w / v) benzalkonium chloride or benzethonium chloride and 0.5% (w / v) D-xylose were prepared (see Table 4).

[0050] Note that the concentration of each test drug aqueous solution is shown in %(w / v), but since this is almost the same as the %(w / w) value (the %(w / w) value is only slightly larger), it is acceptable to interpret it as %(w / w) (i.e., mass%).

[0051] Sterilization test 1 200 μL of the test drug aqueous solution was dispensed into column A of a 96-well plate, and 200 μL of TSB medium for inactivating the bactericidal component and culturing oral bacteria was dispensed into columns B through H.

[0052] Furthermore, since TSB medium can inactivate bactericidal components, the sterilization time can be adjusted by adjusting the timing of its addition. The TSB medium used was prepared by dissolving 30g of Tripticase Soy Broth (TSB), 1g of Yeast Extract, 1g of Hemin / menadion solution, 0.7g of lecithin, and 5g of Tween80 in distilled water, making up to 1L, and then autoclaving the mixture. The Hemin / menadion solution was prepared by dissolving 0.25g of Hemin in 5ml of 1N NaOH, adding 20ml of distilled water, and then mixing in 0.025g of menadion (Vitamin K3) dissolved in 25ml of 99% ethanol.

[0053] 20 μL of saliva was added to column A, pipettered, and then 20 μL each was added from column A to columns B through H at each time interval. More specifically, the measurement started when 20 μL of saliva was added to column A and mixed by pipetting. 20 μL of the solution from column A was then added to column B after 30 seconds, to column C after 60 seconds, to column D after 90 seconds, to column E after 120 seconds, to column F after 180 seconds, to column G after 240 seconds, and to column H after 300 seconds, and mixed by pipetting. After that, anaerobic culture was performed for 48 hours, and the presence or absence of bacterial growth was visually confirmed to determine whether the bacteria were alive or dead. More specifically, if the culture medium was turbid visually, it was determined that bacteria had proliferated and that the bacteria in the solution had not been completely killed.

[0054] Each solution sampled from column A was evaluated after 30, 60, 90, 120, 180, 240, and 300 seconds. The time at which the culture medium was no longer cloudy and the bacteria in the solution were killed was defined as the sterilization time.

[0055] In addition, there were cases where the above operations in the study were set to occur after 60 seconds, 180 seconds, 300 seconds, 600 seconds, 1200 seconds, and 1800 seconds, instead of 30 seconds, 60 seconds, 90 seconds, 120 seconds, 180 seconds, 240 seconds, and 300 seconds.

[0056] Tables 1-4 show the relative sterilization times when each monosaccharide or monosaccharide alcohol is added, with the sterilization time for each subject's saliva using the bactericidal component alone (at the same concentration as the bactericidal component under consideration) set to 100%. For example, if the sterilization time when 0.05% (w / v) of the bactericidal component was mixed with subject A's saliva was 120 seconds, and the sterilization time when an aqueous solution of the test drug containing 0.05% (w / v) of the bactericidal component and 0.5% (w / v) of the monosaccharide or monosaccharide alcohol was mixed with subject A's saliva was 60 seconds, then the relative sterilization time in this case is 50%. Note that blank spaces in the relative sterilization time value indicate that the component was not considered.

[0057] [Table 1]

[0058] [Table 2]

[0059] [Table 3]

[0060] [Table 4]

[0061] Sterilization test 2 An aqueous solution of the test drug was prepared containing 0.05% (w / v) cetylpyridinium chloride, 0.05, 0.1, 0.5, 1, 5, or 10% (w / v) of D-xylose or D-mannitol, 0.01% (w / v) of citric acid, and 0.07% (w / v) of trisodium citrate. 180 μL of this aqueous solution was dispensed into column A of a 96-well plate, and 180 μL of PBS containing lecithin and Tween 80 was dispensed into columns B to H to inactivate the cetylpyridinium chloride. The PBS was Phosphate Buffered Saline (PBS) tablets (manufactured by Takara Bio Inc.), 0.7 g of lecithin, and 5 g of Tween80 were dissolved in distilled water, and the mixture was made up to 1 L and sterilized by autoclaving.

[0062] Then, 20 μL of subject A's saliva was added to column A and mixed by pipetting. This was the starting point for measurement, and after 60, 90, or 120 seconds, 20 μL of the solution from column A was transferred to column B and mixed. Next, 20 μL of the mixture from column B was transferred to column C and mixed, and then similarly transferred to column D. This process was repeated to prepare 10-fold dilutions. 10 μL of each dilution was dropped onto TSA / VH agar medium and spread onto the medium by tilting the plate. TSA / VH medium was prepared by dissolving 40 g of Tripticase Soy Agar (TSA), 1 g of Hemin / menadion solution, 0.7 g of lecithin, and 5 g of Tween 80 in distilled water, making up to 1 L, and then autoclaving it. The hemin / menadion solution was prepared by dissolving 0.25g of hemin in 5ml of 1N NaOH, adding 20ml of distilled water, and then mixing in 0.025g of menadion (vitamin K3) dissolved in 25ml of 99% ethanol.

[0063] After applying a 100-fold or 1000-fold dilution to a culture medium and allowing it to stand for 72 hours for anaerobic incubation, the presence or absence of colony formation was visually determined on TSA agar medium. Table 5 shows the relative sterilization times for the above-mentioned aqueous solutions of the test drugs containing each sugar (D-xylose or D-mannitol), with the sterilization time for the control (a controlled aqueous solution of the test drug prepared in the same manner except for the absence of sugar) set as 100%. In Example 12a, although the relative sterilization time was 100%, the degree of colony morphology at the point when colony formation occurred was lower compared to the control.

[0064] [Table 5]

[0065] The following are examples of prescriptions. Note that the values ​​for each component listed in the table below represent mass percentages.

[0066] <Liquid and gel formulations>

[0067] Table 6

[0068] <Lian Mo Mo Mo>

[0069] Table 7

Claims

[Claim 1] (A) Cationic surfactants, and (B) At least one selected from the group consisting of monosaccharides and monosaccharide alcohols An oral composition containing, (A) is at least one selected from the group consisting of C12-15 alkylpyridinium salts, benzalkonium salts, benzethonium salts, and cocoyl arginine ethyl salts. (B) is at least one selected from the group consisting of xylose, mannitol, arabinose, ribose, glucose, fructose, and sorbitol. Oral composition.

Images